Available online at www.joac.info

ISSN: 2278-1862

Journal of Applicable Chemistry

2023, 12 (4): 444-499 (International Peer Reviewed Journal)





CNN-54--Fit (Figure Image TableScript...) Bases (Bfit) Part 2.xAI.Medicine (xAIM)-2021

Information Source	<pre>sciencedirect.com;ACS.org ;</pre>	
S. Narasinga Rao M D	K. SomasekharaRao, Ph D	R. Sambasiva Rao, Ph D
Associate Professor,	Dept. of Chemistry,	Dept. of Chemistry,
Dept. of General Medicine,	Acharya Nagarjuna Univ., Andhra University,	
Government medical college,	Dr. M.R.Appa Rao Campus,	Visakhapatnam 530 003,
government general hospital,	Nuzvid-521 201, I ndia	l ndia
Srikakulam , AP, I ndia		
snrnaveen007@gmail.com	sr_kaza1947@yahoo.com	rsr.chem@gmail.com
(+91 9848136704)	<u>(+91 98 48 94 26 18)</u>	(+91 99 85 86 01 82)

Conspectus:Data-,information-,knowledge-, intelligence-, method- bases play a pivotal role to understand, design and control desired targets in health, communication, defence and industrial domains. The evolution of data-acquisition methods of increasing accuracy/precision through electronic instruments revolutionised input to output transformation. In addition to numerical/logical/attribute data systems, 2D-/3D-images, figures, multi-way tables and scripts opened new vistas in data-to-information transformation in sub-goals of a task. In this decade, the application of adoptive-trust-worthy-nascent xAI tools in medical sciences changed the scenario of age-old practising protocols. In this communication, select research reports dealing with xAI in medical diagnosis during the year 2021 are briefly described

*Keyword*s:eXplainable/interpretable/Responsible/Trustworthy AI; Machine Learning; Deep architectures; Medical diagnosis; Cancer, Heart/brain/lung diseases; probes for xAI; Health care

	Layout	
Diagnosis	Cancer Heart diseases ECG Analysis ASD COVID-19	
	Drugs	
Health	Toxicology	
	Health-care	
	Framework-	K(nowledge)Lab
	Segmentation	
xAI	Explainability	
	Interpretability	
	Pixel level	
	Shapley-LIME	
	Heatmap	
	Saliency map	
xAI.Probes	CAM Grad CAM	
	tSNE	
	Variable Imp plot	
	Variable Imp plot	

Cancer



Heart diseases







xAI.Med.	Heart		 2021-20
		Explainable prediction model of heart disease	
Carrananananananananan		un an	











ECG Analysis

xAI.Med.		2021-06
	Mach Lrn and xAI	



















xAI.Med.		2021-06
	visual explanation for a single ECG	





455







xAI.Med.	ANNAN MANANANANANANANANANANANANANANANANA	2021-112
	Expert IF-THEN rules	





QUI 100 (100 (100 (100 (100 (100 (100 (100	
xAI.Med.	2021-112
sensitivi	ty, specificity, balanced accuracy, and area under the ROCcurve of the expert algorithm and
	human participants (mean values)





ASD



xAI.Med.





		2021-05
	ASD	



COVID-19

東公司の東京	xAI.Med.	2021-18















vieu.			2021-
	Explanations for the COVID-19 inference of the test set.	the 12 COVID-19 positive patients in	
	ID Decision Tree Explanation		
	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	> -1.74 and EOS \leq -0.61 and MPV > 90	
	$ \begin{array}{ll} \mbox{CRP} > -0.43 \mbox{ and } EOS > 0.63 \mbox{ and } AST \leq \\ \mbox{0.12 and } CREAT > -0.88 \mbox{ and } K+ > -0.8 \end{array} $	-0.41 and UREA $>$ -0.91 and MCV $>$ 52	
	 BOS > 0.54 and WBC > -0.97 and MCV -0.51 and PLT > -2.98 and HGB > 0.96 	$^\prime$ \leq -0.13 and ALT \leq 2.13 and CRP $>$ and Sodium $>$ 0.12	
	4 AST $>$ -0.43 and CRP $>$ -0.46 and PLT -1.29 and EOS \leq 0.76 and CREAT $>$ -0. and PLT $>$ -3.57	\leq 0.26 and WBC \leq -0.44 and LYM $>$ 75 and PLT \leq 0.06 and AST $>$ -0.37	
	5 EOS $>$ -0.59 and CRP $>$ -0.53 and PLT \leq -0.34 and EOS \leq 0.39 and MONO $>$ -0.4 and HCT $>$ -0.50	-0.33 and CREAT $>$ -0.30 and AST $>$ 49 and WBC \leq -0.58 and LYM $\leq~1.11$	
	 6 CRP > -0.50 and MPV > -0.99 and EOS -1.17 and CREAT > -0.64 and EOS ≤ 0.3 and PLT > -4.22 	\leq 0.82 and PLT \leq 0.21 and LYM $>$ 37 and WBC \leq -0.40 and HGB $\leq~$ 0.44	
	7 CRP $>$ -0.52 and PLT \leq 0.08 and EOS \leq -0.87 and EOS \leq -0.67 and RBC $>$ -1.02	-0.07 and HGB > -0.83 and CREAT > 2 and MONO > -0.16	
	8 $$\rm HGB>-0.83$ and $LYM>-1.13$ and CRP >-1.09 and EOS ≤ 0.77 and AST >0.23 and PLT \leq -0.05	$>$ -0.47 and CREAT $>~$ -0.48 and HCT 3 and MCV $>$ -6.31 and WBC $\leq~$ -0.88	
	9 EOS \leq -0.59 and PLT \leq -0.08 and MPV 2.35 and WBC \leq -1.04 and MPV $>$ -0.9	$>$ -1.00 and HCT $>$ 0.48 and UREA \leq 7 and MCIIC $>$ -1.08	
	10 EOS \leq -0.55 and PLT \leq 0.13 and MPV -0.11 and ALT $>$ -1.13 and WBC \leq -0.2	$>$ -1.02 and WBC \leq 0.09 and PLT \leq 9 and MONO $>$ -0.28	
	$\begin{array}{ll} 11 & EOS > -0.62 \mbox{ and } AST > -0.46 \mbox{ and } EOS \leq -0.46 \mbox{ and } CRP > -0.68 \mbox{ and } PLT \leq -0.04 \mbox{ and } AST \leq 1.04 \end{array}$	0.52 and WBC \leq -0.47 and CREAT $>$ and MONO $>$ -0.03 and MCH $>~$ -1.77	
	12 PLT ≤ 0.10 and MPV > -1.04 and EOS ≤ -0.58 and LYM > -1.48 and MCH > -1.4 and MCHC > -0.22	\leq -0.54 and MPV $>$ -1.01 and WBC \leq 48 and HGB $>$ 1.07 and ALT $>~$ -0.54	



	xAI.Med.		2021-33
		Heatmaps generated with an individual CNN (Arch1)	
		for a non-consolidation test X-ray (sample 1).	
20		UN MARANA NA MARANA	



	دAl.Med.	2021-33
	Heatmaps of a non-consolidation sample 1	
-2		307 300 307 307 307 307 307 300 307



xAI.Med.		2021-34
	Heat map pneumonia in chest x-rays	















	xAI.Med.		2021-07
		Crizotinib gene interactions in three different subgroups	
Z		CARARAN MARARAN	***************************************



					2021-0
		rand	lomized analyses	5	
		Subgroups	DR Top Drugs	Randomized Top Drugs	
	2	MOLTE C	Idarubicin	Tetrahydrobiopterin	
	1	MSI-H & no	Dactinomycin Diethylstilbestrol		
Iymphatic invasion Do	Doxorubicin	Fluphenazine			
		MOT IL 9	Cerulenin	Streptozocin	
2 MSI-H sided	MSI-H & right-	Crizotinib	Tetrahydrobiopterin		
		sided colon	Afatinib	Metaxalone	
		MSI-H & right-	Menadione	Testosterone	
	3	sided colon & no	Dasatinib	Pseudoephedrine	
		lymphatic invasion	Vinblastine	Paliperidone	
	2 3		Varenicline	Terazosin	
4	MSS & female	Digitoxin	Isoflurane		
			Gefitinib	Fospropofol	
		MSS & female &	Crizotinib	Imatinib	
	5	have lymphatic	Cerulenin	Simvastatin	
		invasion	Dabrafenib	Bortezomib	
		MOC 0 a history of	Niclosamide	Trilostane	
	6	MSS & a history of	Perhexiline	Doxylamine	
		colon polyp	Digoxin	Flucloxacillin	
		MSS & a history of	Menadione	Diclofenac	
	7	colon polyp & No	Varenicline	Digoxin	
		venous invasion	Crizotinib	Progesterone	

Toxicology Human and Computer Agreement





generaliset and an and a second and a second and a second a second a second a second a second a second a second XAI.Med.	lon de la constante de la const 2021-10
Listing 1: Example rule that represents distribution of salivarates in the general population 0.10::salivation(X,decreased); 0.10::salivation(X,increased); 0.80::salivation(X,usual).	number before the two colons: probability with which the probability is true. A;B means "A or B but notboth".
<pre>assigning the likelihood of one toxidrome over another given thatthe patient is manifesting a symptom. 4*P::hasToxidrome(X,sympathomimetic); P::hasToxidrome(X,serotonergic) :- mentalStatus(X,agitated), P is 0.2.</pre>	 A :- B means that B is true if A is true ✓ The function mentalStatus(X,agitated) is true if patient X is agitated. The function hasToxidrome(X,Y) is true if patient X manifeststoxidrome Y
<pre>Rule Defining the Cholinergic Toxidrome hasToxidrome(X,cholinergic) :- salivation(X, increased), urination(X, increased), %i.e. polyuria pupilDiameter(X,small).</pre>	The relative probabilities across rules were chosen to reflect the perceived relative prevalence of each clinical finding
 Report from American Association of Poison Copoisoning in the US to estimate the prior proba Physical findings, for example the rates of saliva population, are not known. Nor is it known that a patient is precisely four the sympathomimetic toxidrome as opposed to ser after an unknown ingestion. The magnitudes were chosen, in conjunction w components of clinical response 	Introl Centers on the relative prevalence of each bility of each toxidrome prevalence of many ation in the general imes more likely to suffer from a rotonin toxicity if the patient becomes agitated ith the consensus of experts, to reflect implicit

xAI.Med.

2021-10





\mathbf{x}	2021-08

Problem description	The user needs - A description of	to know: of the class				
UI design example	- The prevalence	e of the class				
	Problem	The user needs to kno	100.			
	description	- A description of the	class			
		- The prevalence of th	e class			
	UI design					
	example					
		COSS	Name. Miriam de Jo	ng Gender: F Date of birth.: 01-01-2013 (7 y/o)		
		Suggested pre-diagnosis	Attention-deficit/hype	ractivity disorder (ADHD)		
		Disorder Attention-deficit/hypera	ctivity disorder (ADHD)	is a disorder marked by an ongoing		
		pattern of inattention ar	d/or hyperactivity-impu	Isivity that interferes with functioning		
		or development.				
		Prevalence				
		The prevalence of ADHD estimated at 2.9%. 75%	in children (below the a of children with ADHD a	the age of 18) in the Netherlands is +D are male and 25% are female. The t 2.1%.		
		prevalence of ADHD in a	dults is estimated at 2.1	%.		
2: Available/relevant information	on.					
Problem description	The user needs to k	10W:	2504			
	 The information th The information th 	at is used to make the classificat at is relevant in making this typ	ion e of classification			
II design example						
or delight example	Desklam (D			<u></u>		
	Problem 1. description	ie user needs to know: The information that is a	sed to make the cl	assification		
		The information that is a The information that is r	elevant in making t	his type of classification		
	UI design		B .			
	example					
		DSS Nar	ne: Miriam de Jong Ge	nder: F Date of birth.: 01-01-2013 (7 v/o)		
			tion-deficit/byneractivity	disorder (ADHD)		
		Supported are diagonasis: Atten	wan-activity tryperactivity	unoraci (Aorio)		
		Suggested pre-diagnosis: Atten	50			
		Suggested pre-diagnosis: Atten Available information in this c	ise Availabla	r		
		Suggested pre-diagnosis: Atten Available information in this c Information	ise Available	1		
P 2: Available/relevant informa Problem description UI design example		Suggested pre-diagnosis: Atten Available information in this ci Information Patient demographics	Available			
		Suggested pre-diagnosis: Atten Available information in this ci Information Patient demographics Gender	Available			
		Suggested pre-diagnosis: Atten Available information in this ci Information Patient demographics Gender Age	233 Name: Miriam de Jong Gender: P Data Suggested pre-diagnosis: Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by pattern of inattention and/or hyperactivity-impulsivity that interferes w or development. Prevalence Prevalence The prevalence of ADHD in children (below the age of 18) in the Netherl estimated at 2.9%. 75% of children with ADHD are male and 25% are feer prevalence of ADHD in adults is estimated at 2.1%. used to make the classification relevant in making this type of classification user needs to know: information that is used to make the classification information that is relevant in making this type of classification ualable Information in this case information information <			
		Suggested pre-diagnosis: Atten Available information in this ci Information Patient demographics Gender Age AVL	Available	the age of 18) in the Netherlands is HD are male and 25% are female. The t 2.1%. e classification ng this type of classification Gender: F Date of birth.: 01-01-2013 (7 y/o) tivity disorder (ADHD)		
		Suggested pre-diagnosis: Atten Available information in this c. Information Patient demographics Gender Age AVL AVL parent 1	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 2	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 2 AVL teacher	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 2 AVL teacher AVL teacher AVL other	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 1 AVL parent 2 AVL teacher AVL teacher SDQ	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 1 AVL parent 2 AVL teacher AVL teacher SDQ SDD parent 3	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 1 AVL parent 2 AVL teacher AVL ther SDQ SDQ parent 1 SDQ parent 2	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AvL AvL parent 1 AvL parent 2 AvL teacher AVL teacher SDQ SDQ parent 1 SDQ parent 1	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AvL AvL parent 1 AvL parent 1 AvL parent 2 AvL teacher AvL ther SDQ SDQ parent 1 SDQ parent 2 SDQ teacher	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 1 AVL parent 2 AVL teacher AVL teacher SDQ SDQ parent 1 SDQ parent 1 SDQ parent 2 SDQ teacher SDQ other	Available Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 1 AVL parent 2 AVL teacher AVL teacher SDQ SDQ parent 1 SDQ parent 1 SDQ parent 2 SDQ teacher SDQ tother	Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AvL AvL parent 1 AvL parent 1 AvL parent 2 AvL teacher AvL teacher SDQ SDQ parent 1 SDQ parent 1 SDQ parent 2 SDQ teacher SDQ teacher	Available Available			
		Suggested pre-diagnosis: Atten Available information in this c Information Patient demographics Gender Age AVL AVL parent 1 AVL parent 1 AVL parent 2 AVL teacher AVL teacher AVL other SDQ SDQ parent 1 SDQ parent 1 SDQ parent 2 SDQ teacher SDQ other	Available			

KARARARARARARARARARARARARARARARARARARAR		Ŗ
xAI.Med.	2021-14	
	2021 11	ĝ.
	1991 1997 1999 1997 1997 1997 1997 1997	4









IF 2-Hour_serum_insulin_level ==⁹ ξ THEN print "If your 2-Hour serum insulin level was" ξ ", you would have score of 0.51" ELSE print "Your 2-Hour serum insulin level is not" \$2-Hour_serum_insulin_level ", please see your doctor."

N 2001 / 2001 / 2001 / 20	xAI.Med.	21-16
2/1002/100	Method- flow	



- A XGBoost, EXtreme Gradient Boosting;
- DCA, decision curve analysis;
- \bigcirc C-index, concordance index;

- \bigcirc ROC, receiver operating curve;

Health-care

xAI.Med.	an a	2021-29
	HealthXAI architecture	



Module / data structure
Activity instances and actions
Activity segmentation and recognition
AI explanation
Anomalies feature extraction
Anomaly feature vector
Anomaly level and scores
Behavioral anomalies
Clinical indicators of locomotion anomalies
Computation of anomaly level and activity scores
Detection of behavioral anomalies (DOBA)
Detection of locomotion anomalies (DOLA)
Knowledge-based anomaly refinement
Locomotion anomalies
Overt errors
Personalized dataset D _p of activities and actions
Regression model
Semantic integration layer
Sensor event record
Sensor vocabulary and Position table
Stream processing software platform
Subtle inefficiencies
Trajectory data cleaning and segmentation
Trajectory segments
XAI



- Mechanism repeated until a leaf is reached.
- OutPut :Leaf contains predicted value



xAI.Med. 2021-29
HealthXAI dashboard---screenshot



GM / 1999 .	1999/1999/1	891/11997/11999	1/10191/10197/10197	1400/1400/14	9/169/169/169/	dill dill hill di	91/1097/1097/1097	/169/1699/1699/169	1.6911.6911.6911	669716697166971669	///////////////////////////////////////	///////////////////////////////////////	/169/169/169/1	91/1691/1691/1691	1.6691.6691.66911.6	69716697166971669	1.469/1.469/1.469/1	69/169/1669/166	4/1109/11009/11009/	/169//169//1699/1699/	1.669/1.669/1.669/1.66	9111197111191111991	1.091.091.091.0	91/1997/19997/18	91/1964
%	A T	Ъ.																				0	001	20	
ŧΧ	AI.	.IVIE	ea.																			2	021-	29	1
10																									1
7,000/100		01/07/00	1/11/11/11/11	1001100110	91691691691	6916916916	9//////////////////////////////////////	100110011001100	11111111111111	6916916916916	1/11/1/1/1/1/1	10011001100110	1001100110011	9//////////////////////////////////////	1.0011.0011.0011.0	1971 11971 11971 1192	1491491491	01/101/101/10	1/11/11/11/1	100110011001100	1011/0110110	01100110011001	10010010010010	1/11/11/11	911991

#	Measure	Statement
S 1	UTR	I have the feeling of trust in the system without explanations regarding its prediction of the overall cognitive status.
S2	UTR	I have the feeling of trust in the system without explanations regarding its prediction of the anomaly level of activities.
S 3	HMTP	The system without explanations would help me providing a more accurate diagnosis than the one I would provide without the use of the tool.
54	HMTP	The system without explanations would help me completing the assessment in less time.
S5	ES	Explanations are easily understandable.
S6	ES	Explanations are detailed enough.
S7	ES	Explanations are not lengthy.
S8	ES	Explanations are useful to understand the reason for the system's prediction.
S 9	ES	Explanations are necessary to understand the reason for the system's prediction regarding the overall cognitive status
S10	ES	Explanations are necessary to understand the reason for the system's prediction regarding the overall anomaly level of activities.
S11	ES	Explanations help reducing the learning time on the system.
S12	ES	In general, I am satisfied with the explanations provided by the system.
S13	UTR	I have the feeling of trust in the system with explanations regarding its prediction of the overall cognitive status.
S14	UTR	I have the feeling of trust in the system with explanations regarding its prediction about the anomaly level of activities.
S15	HMTP	The system with explanations would help me providing a more accurate diagnosis than the one I would provide without the use of the tool.
S16	HMTP	The system with explanations would help me completing the assessment in less time.
S17	UTR	The explanations would help me deciding whether the prediction of the system is correct.

Framework--xAI



Segmentation



x I la	2021-13
- MICCAI dataset	



Explainability Interpretability xAI.Med







\checkmark	Tv. volume of the	primary tumor:		

- Ta, maximum cross-sectional area of the primary tumor;
 Ld, vertical dimension of the reginal lymph nodes;
 LDH, lactate dehydrogenase;
 Lv, volume of the reginal lymph nodes;
 - ✓ La, maximum cross-sectional area of the reginal lymph nodes;
 - ✓ Td, vertical dimension of the primary tumor;
 - EBV DNA, Epstein-Barr virus DNA;
 - ✓ BMI, body mass index.













Explainable ensemble Gaussian kernel model





	nanananananananananananananananananana	2021-03
	Interpretability pipeline	
2		



xAI.Med.	2021-04
. <mark>Pixel-level predictions for images</mark>	



xAI.Med.	2021- 04
Color-coded pixel-level predictions for images	
	10 10 10 10 10 10 10 10 10 1



xAI.Med. 2021-13 Explainable AI heatmaps

